Genexine's First-in-Class Therapeutic DNA Vaccine Shows Significant Potential to Extend Survival in Late-Stage Cervical Cancer; Late-Breaking presentation of phase 2 results from a clinical trial of GX-188E in combination with KEYTRUDA® (pembrolizumab) de

Press/Media: Press / Media

Period2022 Sep 7

Media coverage

1

Media coverage

  • TitleGenexine's First-in-Class Therapeutic DNA Vaccine Shows Significant Potential to Extend Survival in Late-Stage Cervical Cancer; Late-Breaking presentation of phase 2 results from a clinical trial of GX-188E in combination with KEYTRUDA® (pembrolizumab) de
    Media name/outletBusiness Wire
    Country/TerritoryUnited States
    Date22/9/7
    PersonsJongeun Lee